The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics has released early results from its ALPHA3 trial, highlighting progress in developing investigational off the shelf CAR T therapy for patients with large B cell lymphoma (LBCL).
The company aims to improve access to novel cell therapies, particularly for patients in community healthcare settings. The ALPHA3 program features an allogeneic, or donor-derived, cell therapy product designed to be readily available and patient centered. The move is part of a broader trend among biotech firms to pursue scalable and more accessible cell therapies that could transform cancer care.
View post on X Loading...
Allogene Therapeutics previously outlined its strategy to address the restrictions of autologous CAR T therapies with its AlloCAR T platform. Earlier this year, the company reviewed initial ALPHA3 safety results and discussed the potential role of cema-cel for minimal residual disease-positive LBCL outpatients in community settings. These efforts reflect the firm’s ongoing focus on investigational cell therapies for broader patient access.